HLA-universal platelet transfusions prevent platelet refractoriness in a mouse model

Human Gene Therapy

Volumn 24, Issue 12, 2013, Pages 1018-1028

  Gras, Christiane ^a   Schulze, Kai ^b   Goudeva, Lilia ^a   Guzman, Carlos A ^b   Blasczyk, Rainer ^a   Figueiredo, Constança ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

^b HELMHOLTZ CENTRE FOR INFECTION RESEARCH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BETA3 INTEGRIN; CD34 ANTIGEN; FIBRINOGEN RECEPTOR; HLA ANTIBODY; LENTIVIRUS VECTOR; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; SHORT HAIRPIN RNA; THROMBOPOIETIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ANTIGEN EXPRESSION; ARTICLE; BLOOD TRANSFUSION REACTION; CELL DIFFERENTIATION; CELL MEDIATED CYTOTOXICITY; CELL PROTECTION; COMPLEMENT DEPENDENT CYTOTOXICITY; CONTROLLED STUDY; CYTOTOXICITY; FLOW CYTOMETRY; HLA SYSTEM; HUMAN; HUMAN CELL; IMMUNE EVASION; IN VITRO STUDY; IN VIVO STUDY; LYMPHOCYTOTOXICITY; MEGAKARYOCYTE; MOUSE; NONHUMAN; PRECURSOR; REFRACTORINESS TO PLATELET TRANSFUSION; STEM CELL; THROMBOCYTE TRANSFUSION; UPREGULATION;

ANIMALS; ANTIGENS, CD34; ANTIGENS, SURFACE; BLOOD PLATELETS; CYTOTOXICITY, IMMUNOLOGIC; DISEASE MODELS, ANIMAL; GENE SILENCING; HISTOCOMPATIBILITY ANTIGENS CLASS I; HUMANS; MICE; PLATELET TRANSFUSION; RNA, SMALL INTERFERING;

EID: 84890542142     PISSN: 10430342     EISSN: 15577422     Source Type: Journal    
DOI: 10.1089/hum.2013.074     Document Type: Article

References (30)

1. Ayala Garc?a, M., Gonzalez Yebra, B., Lopez Flores, A., and Guan? Guerra, E. (2012). The major histocompatibility complex in transplantation. J. Transplant. 2012, 842141.
2. Blajchman, M.A., Goldman, M., and Baeza, F. (2004). Improving the bacteriological safety of platelet transfusions. Transfus. Med. Rev. 18, 11-24. (Pubitemid 38018800)
3. Blajchman, M.A., Slichter, S.J., Heddle, N.M., and Murphy, M.F. (2008). New strategies for the optimal use of platelet transfusions. Hematology Am. Soc. Hematol. Educ. Program 198-204.
4. Buakaew, J., and Promwong, C. (2011). Platelet antibody screening by flow cytometry is more sensitive than solid phase red cell adherence assay and lymphocytotoxicity technique: A comparative study in Thai patients. Asian Pac. J. Allergy Immunol. 28, 177-184.
5. Chen, T.W., Hwang, S.M., Chu, I.M., et al. (2009). Characterization and transplantation of induced megakaryocytes from hematopoietic stem cells for rapid platelet recovery by a twostep serum-free procedure. Exp. Hematol. 37, 1330-1339 e1335.
6. Figueiredo, C., Horn, P.A., Blasczyk, R., and Seltsam, A. (2007). Regulating MHC expression for cellular therapeutics. Transfusion 47, 18-27. (Pubitemid 46006305)
7. Figueiredo, C., Goudeva, L., Horn, P.A., et al. (2010). Generation of HLA-deficient platelets from hematopoietic progenitor cells. Transfusion 50, 1690-1701.
8. Foreman, O., Kavirayani, A.M., Griffey, S.M., et al. (2011). Opportunistic bacterial infections in breeding colonies of the NSG mouse strain. Vet. Pathol. 48, 495-499.
9. Gekas, C., and Graf, T. (2010). Induced pluripotent stem cellderived human platelets: One step closer to the clinic. J. Exp. Med. 207, 2781-2784.
10. Giarratana, M.C., Rouard, H., Dumont, A., et al. (2011). Proof of principle for transfusion of in vitro-generated red blood cells. Blood 118, 5071-5079.
11. Gouttefangeas, C., Diehl, M., Keilholz, W., et al. (2000). Thrombocyte HLA molecules retain nonrenewable endogenous peptides of megakaryocyte lineage and do not stimulate direct allocytotoxicity in vitro. Blood 95, 3168-3175. (Pubitemid 30321169)
12. Handin, R.I., and Stossel, T.P. (1974). Phagocytosis of antibodycoated platelets by human granulocytes. N. Engl. J. Med. 290, 989-993.
13. Hod, E., and Schwartz, J. (2008). Platelet transfusion refractoriness. Br. J. Haematol. 142, 348-360. (Pubitemid 351962170)
14. Klein, C.A., and Blajchman, M.A. (1982). Alloantibodies and platelet destruction. Semin. Thromb. Hemost. 8, 105-115. (Pubitemid 12006548)
15. Levin, M.D., De Veld, J.C., Van Der Holt, B., and Van't Veer, M.B. (2003). Screening for alloantibodies in the serum of patients receiving platelet transfusions: A comparison of the ELISA, lymphocytotoxicity, and the indirect immunofluorescence method. Transfusion 43, 72-77. (Pubitemid 36322899)
16. Lim, J., Kim, Y., Han, K., et al. (2002). Flow cytometric monocyte phagocytic assay for predicting platelet transfusion outcome. Transfusion 42, 309-316.
17. Lu, S.J., Li, F., Yin, H., et al. (2011). Platelets generated from human embryonic stem cells are functional in vitro and in the microcirculation of living mice. Cell Res. 21, 530-545.
18. Matsunaga, T., Tanaka, I., Kobune, M., et al. (2006). Ex vivo largescale generation of human platelets from cord blood CD34+ cells. Stem Cells 24, 2877-2887. (Pubitemid 46053024)
19. Parekh, B.S., Berger, E., Sibley, S., et al. (2012). Development and validation of an antibody-dependent cell-mediated cytotoxicity-reporter gene assay. MAbs 4, 310-318.
20. Rebulla, P. (2002). Refractoriness to platelet transfusion. Curr. Opin. Hematol. 9, 516-520. (Pubitemid 35191122)
21. Reems, J.A. (2011). A journey to produce platelets in vitro. Transfusion 51(Suppl. 4), 169S-176S.
22. Sacher, R.A., Kickler, T.S., Schiffer, C.A., et al. (2003). Management of patients refractory to platelet transfusion. Arch. Pathol. Lab. Med. 127, 409-414. (Pubitemid 36443674)
23. Semple, J.W., Speck, E.R., Milev, Y.P., et al. (1995). Indirect allorecognition of platelets by T helper cells during platelet transfusions correlates with anti-major histocompatibility complex antibody and cytotoxic T lymphocyte formation. Blood 86, 805-812.
24. Semple, J.W., Aslam, R., Kim, M., et al. (2007). Platelet-bound lipopolysaccharide enhances Fc receptor-mediated phagocytosis of IgG-opsonized platelets. Blood 109, 4803-4805. (Pubitemid 46827774)
25. Sharma, S., Sharma, P., and Tyler, L.N. (2011). Transfusion of blood and blood products: Indications and complications. Am. Fam. Physician 83, 719-724.
26. Stephan, F., Montblanc, J., Cheffi, A., and Bonnet, F. (1999). Thrombocytopenia in critically ill surgical patients: A casecontrol study evaluating attributable mortality and transfusion requirements. Crit. Care 3, 151-158. (Pubitemid 30004543)
27. Sullenbarger, B., Bahng, J.H., Gruner, R., et al. (2009). Prolonged continuous in vitro human platelet production using threedimensional scaffolds. Exp. Hematol. 37, 101-110.
28. Takayama, N., Nishimura, S., Nakamura, S., et al. (2010). Transient activation of c-MYC expression is critical for efficient platelet generation from human induced pluripotent stem cells. J. Exp. Med. 207, 2817-2830.
29. Wiita, A.P., and Nambiar, A. (2012). Longitudinal management with crossmatch-compatible platelets for refractory patients: Alloimmunization, response to transfusion, and clinical outcomes (CME). Transfusion 52, 2146-2154.
30. Zaffar, N., Joseph, A., Mazer, C.D., et al. (2013). The rationale for platelet transfusion during cardiopulmonary bypass: An observational study. Can. J. Anaesth. 60, 345-354.